Merck KGaA (MRK) Earnings Call Transcript & Summary

November 13, 2025

Deutsche Boerse Xetra DE Health Care Pharmaceuticals earnings 69 min

Earnings Call Speaker Segments

Operator

operator
#1

Good day, everyone, and welcome to Merck’s investor and analyst conference call covering the third quarter of 2025. During the conference, you may press *11 at any point to join the queue for the question-and-answer session. As a reminder, everyone will be in listen-only mode. Please be aware that, at our customer’s request, this conference is being recorded. I’ll now hand things over to Florian Schräder, Head of Investor Relations, who will guide you through this conference. Please go ahead, sir.

Florian Schraeder

executive
#2

Thanks a lot, Sarah. I’d like to offer a warm welcome to everybody who is on the Merck Q3 2025 results call. I’m Florian Schraeder, Head of Investor Relations at Merck. It’s a pleasure to be with you today alongside Belén Garijo, our Group CEO, and Helene von Roeder, our Group CFO. For the Q&A portion of today’s call, Kai Beckmann, CEO of Electronics and Deputy Chair of the Executive Board; Jean-Charles Wirth, CEO of Life Science; and Danny Bar-Zohar, CEO of Healthcare will be joining us as well. Over the first few minutes, we’ll take you through the presentation’s key slides. Once that’s done, we’ll be glad to take your questions. I’ll now hand things over to Belén so we can begin.

Belén Garijo

executive
#3

Thanks, Florian, and good afternoon everyone — welcome to the Q3 earnings call. I'm on slide 5 now, and I'll begin with this quarter's highlights. As you saw this morning, Q3 brought us solid organic growth across all three sectors. Group revenues organically rose 5.2%, while EBITDA pre climbed 8.8%. The strongest organic sales growth came from Life Science at 6%, with our Healthcare and Electronics businesses following, each posting solid organic growth of 5%. A key highlight this quarter is that Process Solutions kept up its strong performance, showing organic growth above 10% for a third quarter in a row despite rising comparables. We saw very strong order growth year-over-year, and the book-to-bill ratio remains comfortably above one. In Science & Lab Solutions, we got back to organic growth, and that was despite continued near-term headwinds. Within Healthcare, the CM&E franchise largely drove organic growth, up 7%, along with solid N&I performance of 6%, driven by Mavenclad, which hit double-digit growth this quarter. Oncology posted moderate organic growth despite heavy competitive headwinds for Bavencio and rising competition for Erbitux in China from non-comparable biologics.

Belén Garijo

executive
#4

With the SpringWorks acquisition having closed on July 1st, this quarter marks the first time we are consolidating our rare disease franchise, and it added 4% to portfolio growth for Healthcare, performing in line with what we had expected. Turning to Electronics, organic growth came in at 5%, driven by our semi material business. On that note, please keep in mind that Q3 contains one last month of Surface Solutions, as we completed the divestment on July 31st. As for full-year 2025, we are now confirming and narrowing the absolute guidance ranges for net sales, EBITDA pre, and EPS pre. We are holding the midpoints for net sales and EBITDA pre, while nudging up the midpoint for EPS pre. If you turn to slide 6, you'll see an overview of how we performed by business sector. Organic sales growth in the third quarter was, again, plus 5.2%, with Life Science the biggest contributor at almost 6% organic sales growth, once again powered by the stellar performance of Process Solutions. Healthcare posted 4.6% organic growth, driven by strong growth of our CM&E franchise together with contributions from Mavenclad and Fertility, which has returned to growth with support from Pergoveris. Electronics likewise delivered solid organic sales growth, with semi materials up high single digit, while DS&S declined in the low-teens range, in line with expectations.

Belén Garijo

executive
#5

On the earnings side, EBITDA pre came in at €1.669 billion, which is up 8.8% organically compared with the same quarter a year ago. Currency movements worked against us across every sector, whereas the portfolio effect was slightly positive, thanks to what SpringWorks contributed. As we mentioned on the Q2 earnings call, EBITDA pre for Q3 got a boost from the sale of a priority review voucher, which produced a gain of €60 million in Healthcare, and from legislative changes in South America that added a further €59 million of income in CO. Leaving those two effects aside, our underlying EBITDA pre margin held steady at roughly 29%, which is fully in line with what we expect for the full year. With that, I'll pass it to Helene, who will walk you through our financials in more detail.

Helene von Roeder

executive
#6

Thanks so much, Belén. And a warm welcome from me as well. So with that, I'm now on slide 8, and I'll begin by walking through our key figures for the third quarter. Net sales rose 1% to €5.318 billion. Organic growth of €273 million along with a portfolio effect of €34 million was largely offset by FX headwinds of -€256 million. EBITDA pre climbed 3.1% to €1.669 billion, giving a margin of 31.4%, which is up 70 basis points versus a year ago. The group margin got a boost from the sale of a priority review voucher and from legislative changes in Latin America, and those two items together added €119 million, supporting the margin by 220 basis points. EPS pre edged up 0.9% to €2.32 per share. The gains from the priority review voucher and legislative changes I just mentioned have supported EPS pre growth and more than offset the higher interest tied to the SpringWorks acquisition. Our operating cash flow grew moderately, by 4.1%, to €1.518 billion. Net financial debt was up 29.8% to €9.228 billion, mainly reflecting financing for the SpringWorks acquisition through a US dollar bond issuance. Our return to the US dollar bond market after 10 years went very well and further diversified our fixed income investor base.

Helene von Roeder

executive
#7

Demand was more than four times the amount offered, which gave us roughly 25 basis points of pricing leverage and highlights how strongly fixed income investors believe in us. I'll also give a quick note on the results we reported, and at this point I'm on slide 9. EBIT rose 11.3% compared with a year earlier. The financial result fell sharply, from -€54 million to -€99 million, driven mainly by increased interest expense on the US dollar bond tied to the SpringWorks acquisition. The effective tax rate for the year to date came in at 21.2%, which sits inside our guidance range and mirrors the usual quarterly swings across the year. On EPS, reported EPS was €2.07, an increase of 11.3% versus a year ago and in line with the growth in our EBIT. Now let's go to the business sector review, starting with Life Science on slide 10. Life Science posted organic growth of plus 5.9% in Q3. That marked an acceleration from earlier quarters, as Process Solutions kept up its momentum and Science & Lab Solutions came back to growth. As we had projected, Process Solutions carried on its strong momentum, with organic sales climbing 10.3%. That makes the third quarter in a row of low-teens growth even as comps got tougher. Order intake was strong again in Q3, and the book-to-bill ratio remained well above one.

Helene von Roeder

executive
#8

To reinforce our Process Solutions downstream portfolio even more, we said on October 15th that we would acquire JSR's chromatography business. That brings in sophisticated protein A chromatography capabilities, which strengthens what we can offer in the way of protein purification solutions that are more efficient and scalable and that help speed up biopharmaceutical production. Moving to Science & Lab Solutions, organic sales were up 2.5% even though headwinds persisted from US policy changes that are weighing on academic and government lab spending, along with market conditions in China that remain challenging. The US government shutdown did not affect Q3, but we do expect certain effects to show up in Q4. Life Science Services posted organic sales growth of 5.2% against a low comp, powered by our CDMO business, and that is notably bioconjugation for ADCs. As we mentioned at our recent Capital Markets Day, Life Science plans to raise R&D investment step by step toward approximately 5% of sales over the mid term, and the R&D increase in Q3 is absolutely consistent with that goal. EBITDA pre rose 6.1% organically, and the margin was up 20 basis points year over year, which reflects operational leverage. I'm now on slide 11, which gives an overview of how the Healthcare business sector performed. Healthcare posted solid organic sales growth of 4.6% in Q3. Roughly 1% of that growth came from a pull-in from Q4.

Helene von Roeder

executive
#9

At the start of this year, we brought our rare disease franchise together for the first time, which added a portfolio effect of plus 4 percentage points, right in line with what we expected. CM&E once again contributed the most to Healthcare's organic growth, posting 7% organic growth, with every therapeutic area chipping in. Fertility sales organically increased 2%, driven largely by Pergoveris growing very strongly, up 37%. On October 15th, we also announced a voluntary agreement with the US government aimed at speeding up US review timelines for Pergoveris and access to our IVF therapies through TrumpRx.gov. Our Oncology franchise posted 3% organic sales growth, with Erbitux sales climbing 10.3%. Erbitux's performance came from strong growth in Latin America and Europe, which more than offset tougher competition from non-comparable biologics in China, where sales fell in the low teens. Our N&I business grew 5.6% organically in Q3. Mavenclad turned in stellar organic growth of 20.4%, backed by continued strong commercial execution. I'd like to say a brief word about the recent decision from the Court of Appeals for the Federal Circuit, which affirmed the US Patent Office's conclusion that our two Mavenclad dosing regimen patents are invalid. We're disappointed by that ruling and plan to file a petition for rehearing or rehearing en banc.

Helene von Roeder

executive
#10

Belén will discuss the implications afterward. Turning to our pipeline, part two of the phase three pimicotinib study's longer-term results were presented at ESMO, demonstrating rising ORR over time along with continued improvements in key secondary endpoints. Our plan is to launch pimicotinib in 2026 in TGCT. On R&D spend, as we noted on our Q2 earnings call and at the Capital Markets Day, our R&D ratio is going up in H2. Project ramp-up costs are the main drivers, with a small effect coming from the SpringWorks acquisition. Our Q3 ratio of 20.9% aligns with our midterm ambition of around 20%. In total, EBITDA pre came to €818 million in Q3, a margin of 37%. Do bear in mind that this figure includes the €60 million gain from our sale of a priority review voucher, with only modest dilution from SpringWorks. Also, note that Healthcare's margin tends to be lower in Q4 because of seasonality. Let's turn to Electronics on slide 12. Organically, sales rose by 4.8% in Q3. Semiconductor Solutions sales were up in the high single-digit percentages organically, more than offsetting lower DS&S sales. In semi materials, AI and advanced nodes keep driving growth. Beyond that, we're seeing demand from mature nodes in Asia, where new qualifications have allowed us to gain market share.

Helene von Roeder

executive
#11

Regarding DS&S, this quarter came in as we had anticipated. As we said back in Q2, we're expecting 2025 to be a very muted year. Given the typical back-end-loaded seasonality for DS&S, we are identifying Q4 '25 as the trough. We hold a more constructive view on the 3D NAND outlook, driven by eSSDs. That aligns with the perspective Kai and his team presented at the Capital Markets Day '25. In our Optronics business, we delivered moderate organic growth of 2.9%. Organic growth was fueled by resilience in our liquid crystal and OLED offerings, supplemented by a robust portfolio contribution from Unity SC. The EBITDA pre margin rose 150 basis points year on year, reaching 27%, primarily due to accretion from the divestment of Surface Solutions. From this point forward, we anticipate gradual improvement in our Electronics margins. Before I hand things back to Belén, allow me to briefly touch on our balance sheet and cash flow statement as well. As you can see on slide 13, our balance sheet declined by €700 million relative to the end of December '24. Looking more closely at the asset side, cash and cash equivalents rose quarter over quarter, mirroring the US dollar bond issuance and the receipt of proceeds from the divestment of Surface Solutions.

Helene von Roeder

executive
#12

Inventories held steady, and receivables climbed €300 million after a quarter in which we concentrated heavily on collecting cash. Intangible assets came up modestly, by €100 million, reflecting goodwill from the SpringWorks acquisition, partly offset by negative FX. Property, plant, and equipment edged down €200 million, largely on FX translation differences. And other assets fell €700 million, chiefly because of the Surface Solutions divestment plus revaluation effects. Over on the liabilities side, financial debt went up €1.8 billion through the US dollar bond issuance. Pension provisions dipped slightly on actuarial gains. Payables came down €100 million, with current payables declining across all three sectors. Net equity dropped €1 billion, as FX differences — mainly a weaker US dollar — more than outweighed the rise in retained earnings. To sum up, our equity ratio went from 58% at the end of December '24 to 57% at the end of Q3. Moving to cash flow on slide 14, operating cash flow came in at €1.518 billion in Q3 '25 versus €1.456 billion in Q3 of last year. Profit after tax was higher, thanks mostly to the gain on the sale of the priority review voucher and to changes in local legislation in Latin America.

Helene von Roeder

executive
#13

That €166 million year-over-year difference in other assets and liabilities comes from variable compensation and a tax adjustment. Other operating activities were down €181 million from a year earlier in Q3 '25, mostly because gains from the PRV voucher and the Surface Solutions divestment were neutralized. The net cash used in investing activity reflects the SpringWorks acquisitions as well as the Surface Solutions divestment. CapEx on PPE came in €63 million lower, which is in line with the updated full-year guidance of €1.5 to €1.7 billion, down from €1.6 to €1.8 billion previously. The shift in financing cash flow is explained by proceeds from the US dollar bond issuance. Finally, as I said at the Capital Markets Day, inside CDMO we are actively reviewing our mRNA and viral vector activities, with potential financial implications in the coming quarters. With that, I'll hand it back to Belén for the outlook.

Belén Garijo

executive
#14

Thanks a lot, Helene. Before we open things up for Q&A, let's take a closer look at slide 16 and our guidance for the full year. As you've probably seen in the press release, we've tightened our group sales guidance to a range of €20.8 to €21.4 billion, and the midpoint is unchanged at €21.1 billion. FX is still a significant headwind, and we've refined that to -5% to -3%, versus the earlier -5% to -2%. Our guidance for organic net sales growth now sits at around 3%, which remains within the range we communicated previously. Moving on to EBITDA pre, we've likewise held the midpoint at €6.1 billion and narrowed the absolute range to between €6.0 and €6.2 billion. Organic sales growth has been narrowed from the previous plus 4% to plus 8% down to plus 5% to plus 7% now. For EBITDA pre, we expect an FX impact between -6% and -4%, adjusted from the prior -6% to -3%. We've lifted the midpoint of our EPS pre guidance by 5 cents, and we now guide a range of €8.20 to €8.60. To give you some additional color, let's look at slide 17. In line with our approach across the group, we're narrowing our organic sales growth guidance to plus 4% to plus 5%, while reaffirming the midpoint at 4.5% for the full year.

Belén Garijo

executive
#15

We're likewise holding the midpoint at 5% for EBITDA pre and tightening the guidance to a corridor of plus 4% to plus 6%. Within Healthcare, we expect organic sales growth of roughly 3%, at the bottom end of the plus 3% to plus 5% range we communicated previously. That mirrors the underlying trends seen year to date along with a degree of uncertainty for Q4 tied to the recent Mavenclad news that Helene mentioned earlier. For organic EBITDA pre, guidance now stands at plus 9% to plus 11%, in line with the sales adjustment and inside the corridor we communicated in August. As a portfolio effect, SpringWorks is now expected to contribute €180 million in sales, raised from the €170 million guided previously, along with EBITDA pre of between €0 and -€20 million, markedly better than the -€70 to -€90 million communicated before. In Electronics, we project organic sales development of between -3% to -1%, narrowed from the earlier -5% to -1% range. Organic EBITDA pre for Electronics is now anticipated at between -11% to -7%, versus the earlier guidance of -15% to -7%. Now, moving to 2026, where I'm certain you're looking for a bit more transparency. At our Capital Markets Day recently, we gave you an early indication of group sales and margin for 2026.

Belén Garijo

executive
#16

You might at this point be asking what the recent Mavenclad news means, specifically the loss of exclusivity coming in the US. Not surprisingly, that is going to affect the 2026 sales and earnings projections for Healthcare. How big the effect turns out to be will depend on the phasing of US generic launches and on our capacity to drive volume in markets outside the US as well, and Danny can give you more detail later in Q&A. So we will be watching developments closely on those fronts, meaning US generic launches, and we will update all of you in Q4 with a full-year guidance. In any event, for your modeling you should assume that Healthcare margins remain north of 30%. Turning to the group, first of all, we see our early 2026 indication for the group, given at the Capital Markets Day, for sales within the range we provided, trending toward the lower end. On group margins, you can be sure we remain laser-focused on mitigating the potential impact of Mavenclad erosion in the US. While acknowledging staged cost mitigation measures, you could assume a margin of around 28% for 2026. As I said, more to come at the Q4 earnings, when we will give a full-year guidance to all of you.

Belén Garijo

executive
#17

All right, Florian, I'll hand it to you now to guide us through today's Q&A.

Florian Schraeder

executive
#18

Thanks, Belén and Helene, for walking us through the slides. Actually, there's one small correction to something we said, and that's at group level the organic EBITDA growth, which has been narrowed from the previous 4% to 8% down to now 5% to 7% — not the organic sales growth. With that, Sarah, I'm very happy to hand things over to you to run the Q&A portion of the call.

Operator

operator
#19

Thank you. We're moving into the question-and-answer portion now. Should you wish to pose something to our speakers, key *11 on your phone's keypad at this point to join the queue. After we've announced your name, you'll be able to ask your question. If speaker equipment is what you're on today, kindly pick up the handset before you make your selection. Please hold for a moment while we take the first question. Today's opening question comes from Matthew Weston of UBS.

Matthew Weston

analyst
#20

Go ahead, please. Thanks so much. I have two questions, if I may — both about Pharma and the 2025 guidance. Belén, you highlighted the SpringWorks guidance change, and we've seen a really sharp swing in the profitability you expect from inorganic this year. I'd like to understand what's different in how you're assessing SpringWorks. Have you cut costs? Have you gotten more revenue leverage? That assumption change looks quite dramatic. My second question concerns what offsets that within the guidance — namely the downgrade to organic Healthcare growth. I'd like to know whether that also reflects an assumption that Mavenclad US generics come in on the 22nd of November, as you flagged earlier in the release about the patent board decision, or whether it's another part of the business that's performing worse?

Belén Garijo

executive
#21

Thanks, Matthew. I’ll ask Danny to take the two Healthcare questions.

Danny Bar-Zohar

executive
#22

Thanks, Belén. Hi, Matthew, and thanks for your questions. I'll start with the SpringWorks question about Q3 margins. It's fairly technical. Our initial guidance reflected a cautious stance. As you'll recall, that first guidance came out just several weeks after the closing. On cost, we took a fairly cautious stance for it. Now, going forward, as you can see, we've raised the portfolio guidance from €170 to €180 million — that's a gain. For the SpringWorks therapeutics compounds, we do expect sequential sales growth in Q4. We do expect an EBITDA pre loss in Q4, a bit above Q3 because of how investments are phased. Overall, you're absolutely right: most of the assumptions were cautious regarding the cost of SpringWorks marketing and sales, and somewhat on R&D. On EBITDA pre at the Healthcare level, what did we communicate? We communicated an update to the top line of around 3% growth rather than the 3% to 5%. What's driving that? First and foremost, as Belén said, looking at the nine months year to date, we see the trends on Erbitux, we see the trends on Gonal-f, on Bavencio.

Danny Bar-Zohar

executive
#23

Just that factor alone would land us, I'd say, in the bottom half of the guidance we gave before. On top of that, within Q3 for Healthcare, that 4.6% growth is overstated by roughly 1% — there's a pull-in from Q4. That's the second piece. Then comes the final one, which is the uncertainty about how Mavenclad will be affected in Q4, and I'm certain we'll be getting questions on that later. As for the EBITDA guidance for Healthcare, we raised it a little. What it captures is, on the downside, the updated sales figure — about 3% rather than 3.5% — and the updated FX headwinds, while on the upside there's the pull-up of the portfolio effect related to SpringWorks. I hope that gives you the bigger picture.

Matthew Weston

analyst
#24

Danny, that's great, thanks. If I could just ask one really quick follow-up: could you tell us, for that 1 percentage point of pull-in from 4Q, what the product breakdown looked like? Which drug should we be looking at?

Danny Bar-Zohar

executive
#25

Yeah. Thanks. That's a solid question. When it comes to regions, the main impact was in the Middle East and Africa, driven by the tensions there — or rather, the tensions in the Middle East that keep fluctuating. People tended to play it safe and stock up somewhat ahead of time. We're mainly talking about CM&E, plus a small amount of Erbitux.

Matthew Weston

analyst
#26

Much appreciated. Thank you.

Operator

operator
#27

Thanks. Our next question comes from Richard Vosser at JPMorgan. Go ahead, please.

Richard Vosser

analyst
#28

Hello, and thank you for allowing me to ask my questions. First, a quick follow-up regarding Mavenclad. Danny, I believe Belén mentioned that you might provide additional detail on Mavenclad and the assumptions for '26 concerning growth, the arrival of generics, and so on, for both the US and growth outside the US. Some of that detail would be excellent. Second, on Electronics, it appears that Surface Solutions, as I think we all recognize, was a lower-margin business, so margins should be improved going forward as a result. There has also been a slight broadening of growth, with elements beyond perhaps semi materials outside of only traditional AI. Could you perhaps discuss what that implies for growth, for the gross margin of that, and for margins going forward in the Electronics business? Many thanks.

Danny Bar-Zohar

executive
#29

Alright, Richard, thanks for asking about Mavenclad—and yes, I think it makes sense to give you a bit more detail here. Let's step back for a moment. Sales this quarter came in at €304 million, which is exceptional growth of 20%. That 20% growth is split pretty much evenly between North America and Europe, reflecting very strong commercial execution. So when it comes to what's next, how should we be thinking about it? Europe, which accounts for roughly 1/3 of revenue, should keep growing in 2026. That part is clear. On the US side, we are definitely not in a position to speculate. Technically, there is one single company holding a tentative FDA approval for a generic version of Mavenclad, and the earliest that could possibly convert to a full approval is the 22nd of November. Now, per FDA guidance, a request to convert from tentative approval to final approval is generally assessed within three months. We don't have full clarity on where that is going to land. As for 2026, it's a little bit premature to say. Why? Because the timing of a generic entry is still unknown. We can think about something around early 2026, and we don't know about other generics.

Danny Bar-Zohar

executive
#30

No other generic has FDA tentative approval, though we are aware of other generics. It is in the public domain. A petition is ready for us to file. Beyond that, generics are generics, and the competitive game and pricing strategy do not always unfold as expected. Clearly, as Belén said, what we shared at Capital Markets Day regarding the top line will need adjusting. As for the staged cost mitigation Belén mentioned, that applies to the US only. Much will hinge on timing and on the phasing of who follows the first generic. Once the first generic arrives, we can keep competing and ought to keep investing at a moderate level. The good thing about the US is that once the dynamics become visible, we can move very quickly and adjust costs appropriately. One last point: to repeat what Belén said, with all the negative top-line impact we anticipate for Healthcare in 2025, costs will be controlled and margins will be controlled so they come in north of 30%.

Jean-Charles Wirth

executive
#31

Second attempt. Richard, I'll take the semi question regarding margin. Let me give you a little more detail on that. Our EBITDA margin improved steadily during Q3, now sitting at 27%, and the exceptional items you observed in Q2 '25 are now behind us. Even so, in Electronics we remain short of where we'd like to be. Those margins ought to be higher, yet the largest gap holding back the acceleration is volume acceleration along with our midterm goal of mid to high single-digit organic sales growth. During Q3, we see support from the initial two months in which Surface is deconsolidated. On an annualized basis, from the Surface Solutions divestment we anticipate 100 basis points of margin accretion. We're also seeing the ongoing advantage of operational leverage in semi materials plus favorable mix for materials serving AI applications and advanced nodes. Some support also came in Q3 '25 from the release of certain provisions. Keep in mind that the investments we make in capacity under our local-for-local strategy are the largest factor behind lower margins. Investments such as the new Taiwan site are assisting us in mitigating tariffs operationally and in gaining share through new qualifications.

Jean-Charles Wirth

executive
#32

Our expectation is that we'll finish the year with margins in the high 20s, and the guidance implies a 26% to 27% EBITDA pre margin. Obviously, there's still work ahead of us, but that's a clear indication of progress, Richard.

Operator

operator
#33

Thanks. We're moving on to the next question now, which comes from Shyam Kotadia at Goldman Sachs. Go right ahead.

Shyam Kotadia

analyst
#34

Thanks for taking my question. I’ve got one about the SpringWorks assets. Looking quarter over quarter, it looks like Ogsiveo sales were pretty much flat. With your portfolio effect guidance for Healthcare assuming €180 million, and since you delivered €85 million in 3Q, that suggests €95 million of sales in 4Q. My guess is most of that €10 million step-up in 4Q could come from Gomekli, because it’s earlier in the launch and given the recent growth momentum. That would again suggest Ogsiveo is relatively flat in 4Q. I just wanted to verify what’s behind that flat quarter-on-quarter revenue assumption for Ogsiveo, and do you expect a growth uplift there? That’s the first question. Then my second question is on SLS. I saw some positive phasing dynamics in the release in the chemistry subdivision. How much of that supported the low-single-digit organic growth this quarter? Since it was a phasing impact, how should we think about 4Q for SLS? Also, if you could quantify the potential impact from the government shutdown, that would be great. Thank you.

Danny Bar-Zohar

executive
#35

On Ogsiveo, let me add a bit more detail. Third-quarter sales reached €62 million, up 38% versus the prior year, making it essentially our strongest quarter since launch. The product debuted exactly two years ago, so it's not a particularly new launch. Underlying demand remains solid, with new patient starts and refills, plus discontinuations staying low. Ogsiveo is the standard of care, with over 70% share of first-line systemic new patient starts. That matters a great deal to us. Why do we have confidence in Ogsiveo? We observed the surgery rate fall from 70% before launch to 50% within 18 months of the US launch. Satisfaction levels among patients and prescribers are very high. 90% of prescribers intend to prescribe it again. The drug appears in the NCCN guidelines. Refills are high, above 90%. Real-world data point to very positive feedback from physicians and patients alike. Long-term efficacy and safety data we published a couple of weeks ago show response rates rising clearly over time, sustained quality-of-life improvements, and a very consistent safety profile. We are definitely, definitely excited about that.

Danny Bar-Zohar

executive
#36

What we have to do is keep driving leadership as the first-line systemic treatment of choice, and keep expanding the systemic treatment market for desmoid tumors by educating physicians and patients. Then, regarding the flattening you mentioned, we're changing practice here. This is the first in disease for this indication, this rare indication. In certain cases, you need to, I'd say, do a great deal of education when it comes to mobilizing patients. As I said at the Capital Markets Day, with Ogsiveo we're now moving — and I believe SpringWorks has moved into this phase just between signature and closing — into the second phase of the launch. That's the phase where the bolus of patients waiting at the center of excellence for the first drug ever have already been treated. The task now on us is to mobilize those patients under what we call active surveillance into therapy, and to increase the number of new patients, to increase the funnel. I'm referring back to two other things I said when we announced the deal. One, expect volatility. Second, we need to deepen penetration in the US. The potential of more than 20,000 diagnosed patients in the US only is huge, and the vast majority are sort of stuck with symptoms but no decision how to treat these, and these are the patients that we need to get.

Danny Bar-Zohar

executive
#37

We’ve got this, and that’s precisely what I was getting at when I mentioned during the closing that it hinges on what we do in the US. Now, turning specifically to Q3 and chronic disease, summer seasonality is something we do observe. If you break that down by month, the seasonality becomes quite clear. As for Q4, you saw that overall we came in a bit above the SpringWorks guidance. That covers both compounds; we won’t be giving any further split. I also wouldn’t expect the same dynamics you may have noticed between Q3 and Q4 of last year, which, as SpringWorks communicated, came about from increased stocking ahead of a price increase. We’ll keep this under conscious control. We expect to keep seeing broadly consecutive growth, and we’re super excited about the recent Germany launch. We launched 3.5, 4 weeks ago, and I spoke with a commercial lead there, and I’m very, very pleased with how both Ogsiveo and Gomekli are progressing. You’re absolutely right about Gomekli. A fantastic launch, as it looks right now in the US, €23 million, 73% growth quarter over quarter, across both the adult and pediatric population. We feel very confident about this product.

Jean-Charles Wirth

executive
#38

Shyam, I'll give you my overall take on SLS. Regarding Q3 — yes, we got back to positive organic growth in Q3 even with a difficult environment. If you dig into it, biomonitoring was a strong driver from a portfolio standpoint, and that was partly true for chemistry and Lab Water too. Looking at regions, Europe was the main driver. I'd also like to mention that several months back we started an initiative centered on customer focus. What I mean — what we mean — by customer focus is this: within SLS we've focused on strengthening our supply chain, especially on inventory management and fill rates, so the customer experience improves. Yes, we saw a nice and meaningful benefit on chemistry, but that's a one-time effect. Going forward, we're observing a degree of sequential stabilization in academia, government, and hospital, though the market stays volatile. Let me give you two concrete examples. The first is China, which we continue to view as a muted market tied to the geopolitical situation, local competition, and so on. The second key driver I want to flag as we look ahead is the US government shutdown, which created a degree of uncertainty in the market, particularly for our academic, government, hospital customer segments.

Jean-Charles Wirth

executive
#39

We observed, I'd say, a decline in weekly order intake in the US across recent weeks. The positive side is that the shutdown ought to be over at this point, though it did affect the opening weeks of Q4.

Shyam Kotadia

analyst
#40

Much appreciated.

Operator

operator
#41

Thanks. Our next question comes from Charles Pitman-King at Barclays. You have the floor.

Charles Pitman-King

analyst
#42

Hi, thank you so much for taking my questions. So just a first question, please, on how you're thinking about the fertility business — just thinking about how Gonal-f performed in the quarter versus consensus, a little bit weak, but also thinking a bit more broadly about next year. Now that you've signed your MFN agreement with the US administration to improve access to your fertility business, what sort of dilution should we really be expecting to be reflected in FY '26, or do you expect that to be offset by volume rises due to improved access? Just wondering if you can confirm this is expected to eliminate the rest of your portfolio tariff risk as a result of the agreement, just given that that happened about a couple of hours after the end of your CMD. Then just a second question, I'm not sure, I may have missed it earlier, apologies, I had to join late, but can you just confirm what the driver was of the lower dilution seen from the SpringWorks acquisition for the third quarter and why you're now only expecting €10 million for the year? Is it just the better-than-expected sales seen for Ogsiveo and Gomekli that you were just referencing?

Charles Pitman-King

analyst
#43

Thanks.

Danny Bar-Zohar

executive
#44

Sure, happy to take that. I'll begin with the second question since it may be the briefer one. The main factor behind the reduced dilution of SpringWorks in Q3 — we shifted it from a midpoint of -€70 to a midpoint of -€10 — is largely the very cautious stance we adopted just a few weeks after closing the deal, regarding commercial and R&D spend. We're now loosening some of that cautious stance a bit. On the spending side, part of it will shift into Q4, but on the whole, that's the primary explanation for the smaller dilution. I hope that's helpful. Turning to fertility, the third quarter came in at €360 million for the franchise, up 2% organically, and that was pretty much what we expected. It's the first quarter this year that returns to growth; the prior two were flattish to minus low single digit. By region, yes, a double-digit decline in North America due almost exclusively to Gonal-f price erosion, as we flagged over the last couple of quarters. That North America decline was more than offset by growth across all other regions: first Europe, then Asia-Pacific, Middle East, Latin America. On the brands, a high single-digit decline in Gonal-f, driven, as we said, in North America by negative price effects and in the US, and in China, as has been the case over the last two quarters, what I'd still call temporary market softness in China in a rather competitive environment with local biologics and local hMGs.

Danny Bar-Zohar

executive
#45

Those gains were mostly cancelled out by double-digit expansion — Pergoveris rising almost 36%, 37% across every region. The profile this drug delivers is highly differentiated, while the remaining fertility products posted only modest growth. That captures where things stand today. Turning to 2026, we expect low single-digit growth, since near-term headwinds — Gonal-f price erosion plus somewhat muted market growth in China — will be more than offset by Pergoveris continuing its strong trajectory. We anticipate launching Pergoveris in China during the first half of 2026, which matters a great deal to us. As you noted, we are pursuing a US launch of Pergoveris in the second half of 2026 under the commissioner's national priority review voucher program. I would call this breaking news, coming right on the heels of the Capital Markets Day: a private-public deal struck with the White House. Our plan is to file Pergoveris with the US FDA within the next couple of weeks, once the shutdown ends. Should approval come with a broad label, we hope for significant upside in the US and globally. Over the mid-term, fertility should grow at a mid single digit rate, as we stated at the Capital Markets Day.

Danny Bar-Zohar

executive
#46

So the main growth drivers for fertility: first, a market that's expanding because IVF demand keeps rising and access is improving in lots of places—Asia-Pacific, Europe—plus reimbursement, and then Pergoveris picking up share. We also plan to bring Pergoveris Pen to market as a replacement for the vial across several markets, and that should give us an extra lift. There are risks: biosimilars pushing further in, and most of those risks sit with Gonal-f in China and Europe, but our confidence in this forecast is very high. On tariffs—the second piece of the agreement with the White House; the first piece covered DTC for Gonal-f and Pergoveris; the second piece was a letter of intent with the Ministry of Commerce, where the goal, once we wrap up this conversation, is really to keep pharmaceutical products and ingredients out of the 232, out of the Section 232 tariffs. We're negotiating with very good intent to get us relief from pharmaceutical tariffs going forward.

Charles Pitman-King

analyst
#47

Much appreciated.

Operator

operator
#48

Thanks. We’re ready for the next question now. It comes from Peter Verdult at BNP Paribas Exane. Please go ahead.

Peter Verdult

analyst
#49

Thank you, Peter Verdult, BNP. Danny, can we return to fertility for a moment? Specifically, how significant a medium- to long-term value driver that's underappreciated is the deal you've completed with the US? I heard everything you said in response to the earlier question. Could you perhaps help us with a baseline as we exit 2025 — what's the run rate for Pergoveris? Most people on this call, I think, would view fertility as a franchise growing at mid-single digits. I don't want you to repeat all the dynamics you've just described, but I do want to ask: when you consider that government deal, the volume opportunity, and the fact that you're not yet in China and Japan with Pergoveris, does the management team think of fertility as mid-single-digit growth, or do you begin to think about upside to that? Baseline on Pergoveris and the medium- to long-term outlook for fertility. Thank you.

Danny Bar-Zohar

executive
#50

Thanks, Peter, for raising that, and let me make it clearer. You're completely right. For fertility across the whole of this year, what we're expecting is roughly flat organic sales growth. You noticed the impact — quite a muted impact — in the first 2 quarters, coming back to growth, getting our heads above water over the coming couple of quarters. That's what you should be expecting for this year. Turning to Gonal-f, I'd say expect a decline. Our broad view is that the mid-term outlook for Gonal-f will be stable. On one side, we see the drivers I mentioned earlier; on the other side, we'll see biosimilars, price pressure, and to some degree partial cannibalization from Pergoveris. Now, on the US deal, here's how you should think about it: we commercialize Gonal-f through 2 channels. One is the private channel, a cash-paying channel, and the other is managed care via PBM, okay? The White House deal pertains to the private one. This discount, or rebate, of about 83% that we're giving brings the price in the private channel, generally speaking, into the same range as the one currently in the public channel.

Danny Bar-Zohar

executive
#51

I'd add that since contracts with managed care channels are still in place, I'd anticipate further erosion over the next year, and then eventually in later years — though not in 2026 — we'll begin to see, I'd say, a stabilization. Pergoveris should largely offset this, and it is, in my view — and not only mine, but also that of key opinion leaders and patients — a huge innovation. In every market where Pergoveris is available, both Pergoveris and Gonal-f are performing better. That makes us very excited about this drug's potential. Thank you. Naturally, we confirm mid-single-digit for fertility overall. I don't believe we're at the point of changing it either upward or downward. We need to see how the mix plays out.

Peter Verdult

analyst
#52

I appreciate that.

Operator

operator
#53

Thanks. We'll take the next question from Olivier Metzger at ODDO BHF. You have the floor.

Olivier Metzger

analyst
#54

All right, good afternoon, and thanks very much for taking my questions. My first one concerns Healthcare and is really strategic in nature. Given the recent news about Mavenclad and the loss of exclusivity, how has that, let's say, altered the way you look at the MS business overall? And for a second question, in your qualitative remarks on LSS, you mentioned some higher demand coming from early biotech. Do you see that as a sustainable improvement, or would you still characterize it as quarterly volatility? Thank you.

Danny Bar-Zohar

executive
#55

On the Mavenclad patent expiry and what it means for the multiple sclerosis business. Like I mentioned earlier, the exclusivity loss did arrive in the US 10 months, 11 months sooner than we had anticipated. In Europe, regulatory exclusivity runs out in August 2027, and following that we hold SPCs country by country. Europe's circumstances are well understood, and our expectation is that Europe, or ex-US, will keep growing where Mavenclad is concerned. Turning to the US, as I noted at the start and as has come up a couple of times, we'll have to handle that decline in the right way. We possess every plan and all the capabilities needed for that, and to react as quickly as we can. Over the longer term in multiple sclerosis, you're fully aware of where our pipeline stands in that area. We have no further products in this field. What we'll do — and I said this at the Capital Markets Day regarding Mavenclad, which arrived slightly sooner — is manage the Mavenclad decline for cash, meaning a profitable decline handled properly. I hope that provides you with more color on the matter.

Olivier Metzger

analyst
#56

Yes.

Jean-Charles Wirth

executive
#57

Oliver, Jean-Charles here. Regarding your question about SLS, we can confirm that we're seeing some positive green shoots from the pharma company that impacted Science & Lab Solution as we move forward. That said, I want to restate what I mentioned regarding China. On a short-term basis, demand in China is looking quite muted. Even so, China remains a very important strategic pillar for Life Science overall. In this context, a few weeks ago we announced a new go-to-market transformation. We're making solid progress. Just 24 hours ago, we named the new head of China. Again, this underscores the fact that China remains very, very important to us. Last but not least, I'd also like to repeat that we are seeing some impact stemming from the US shutdown on our academic customers in North America.

Olivier Metzger

analyst
#58

Thanks a lot.

Operator

operator
#59

Thanks. We'll move on to the following question now. It comes from Florent Cespedes at Bernstein. The line is yours.

Florent Cespedes

analyst
#60

Good afternoon, and thanks so much for taking my questions. I have two quick ones, please. First, for Danny on Pharma and the pipeline: could you perhaps tell us which key milestones we should be looking for in 2026 when it comes to clinical trial readouts? My second question is for Kai, on Electronics, DS&S: why do you expect this business to stabilize in 2026? Thank you.

Danny Bar-Zohar

executive
#61

Florent, thank you. I'll handle the first question. Key milestones: to start, you should anticipate phase three trial starts for prexasertib, the ADC in third-line colorectal cancer. As I noted, and as David also noted at the Capital Markets Day, we're in active partnering discussions given the potential size of this program, including in second line and first line. You should expect a data release in 2026 — initial data from the pan-tumor trial for that compound. We're testing it in pancreatic, gastric, and lung cancer in a basket study. That covers prexo. You should expect enpatoran to enter a phase three trial in lupus rash. We finished the interactions with the regulators, very fruitful interactions. Those are the big-ticket items. The myasthenia gravis with cladribine is enrolling patients, the phase three. Of course, super important — it's not a trial, it's a drug in registration, and we're expecting the launch of pimicotinib in China and also in the United States. In China, it's currently under review; in the US, it's going to be submitted in the next few days. We had the shutdown thing, but it's going to be released. We are also going to get to a data-based decision on the PARP1 selective.

Kai Beckmann

executive
#62

Florent, I'll handle the DS&S question. Let me pick up from where we began in Q2 with our messaging. Back in Q2 '25, we anticipated a sales decline of €200 million to €300 million. That was the organic sales downside we referenced in Q2. Now, three months later, we can confirm it's slightly more than the €200 million, which was our optimistic case — so that's the range we were in. The downside is mostly projects and related equipment. We have seasonality in the large capital equipment and project business, and a lot of revenue there gets booked at year end. You can see that since we acquired Versum, Q4 was often seasonally the highest sales quarter of the year. Since we've now seen €100 million of downside in the first nine months of the year, that means a counter-seasonal downside of another €100 million in Q4 '25 to reach the slightly more than €200 million I just mentioned. We're now calling Q4 '24 the bottom for DS&S, and that's why when you do the math on the Electronics guidance, expect Q4 '24 — it's our lowest sales quarter of the year.

Kai Beckmann

executive
#63

If you follow that guidance, the midpoint is roughly 7% lower organically and about €200 million lower once you factor in the Surface divestment too. That's the bridge for Electronics and, more specifically, for DS&S. Given our order pipeline and the very low base for projects, we anticipate 20 a stabilization for 2026.

Florent Cespedes

analyst
#64

Alright, thanks a lot.

Operator

operator
#65

Thanks. Our final question this afternoon comes from Simon Baker at Rothschild. Go right ahead.

Simon Baker

analyst
#66

Thanks for the question. I have two, if I may. First, back to Pergoveris in the US. Danny, you mentioned that with the shutdown now resolved, you'll be filing within the next couple of weeks. These national priority vouchers come with a 1- to 2-month review period, so could you explain what else remains to be done before we can reach a US launch in the second half rather than the first half? Then a question on SpringWorks, specifically on how the integration costs are phased. It appears that more was taken in Q3 than we had perhaps anticipated, so I was wondering whether you could give us a sense of the phasing and cadence of SpringWorks-related costs on acquisition and integration. Thanks very much.

Danny Bar-Zohar

executive
#67

Thanks. Regarding Pergoveris, I'd describe this as a new kind of exercise for us involving the commissioner's national priority review voucher, and it's equally new to the FDA. On that front, even with the shutdown, we remain in active discussions with that specific division, and we're getting the file ready. We have what's needed for preparing the file. Preparation has to be based on data that went to the EU regulators. Since no trials were conducted in the United States on Pergoveris, there's work that must be done in that regard. After that, we need to have this reviewed. The up to 60 days is, I'd say, a leading assumption on the FDA's part, but we need to see how it plays out because the drug still hasn't been tested in the United States. We also want to ensure we have the right label for this drug and get ready for this launch. Yes, theoretically, you could see that at the very end of H1 2026. We'll keep you updated as we go, since we're relatively early in this process. On the SpringWorks integration, we actually have a positive update on integration and transaction costs, which we now expect at approximately €250 million in total versus the €260 million we communicated previously, €300 million originally.

Danny Bar-Zohar

executive
#68

To break it down, we’re standing by our estimate of €200 million for integration costs, and we’ve brought our assumption for transaction costs down a bit, to roughly €50 million. The earlier figure was 60, reflecting somewhat lower legal costs. I hope that clears things up. Great.

Simon Baker

analyst
#69

I really appreciate it.

Operator

operator
#70

Much appreciated. At this point I'll turn the conference back over to Florian Schräder, who has some closing remarks for us.

Florian Schraeder

executive
#71

Thanks, Sarah, and thanks to all of you for staying interested in Merck. That wraps up our Merck Q3 '25 results call, and we hope to see plenty of you at the roadshows we have coming up. Thanks, and goodbye.

Operator

operator
#72

Ladies and gentlemen, we appreciate you being with us. That brings this call to a close. You’re free to disconnect now.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Merck KGaA transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Merck KGaA earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Merck KGaA or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.